ABSTRACT
Rheumatoid arthritis is chronic infiammatory disease that affects the joints. This results in painful joints, swelling and stiffness in the joints. The present prospective comparative study aimed to compare the USG Doppler findings with the infiammatory marker levels in being a better predictor of joint erosions in rheumatoid arthritis. Total 50 patients coming rheumatology and medicine OPD were studied for infiammatory markers and ultrasonography findings. Radiological investigations such as High resolution USG power Doppler (4-12 MHz) and x-ray of the affected joints were carried out. Majority of participants (60%) belonged to 31-50 years of age group and female gender (86%). The change in infiammatory markers were found to be poorly correlated to joint erosions, while that of USG erosions was found to be strongly positively correlated with the same. Multivariate regression analysis showed that in presence all others also only delta USG erosion significantly impacts delta VDH, or the gold standard(X Ray) for evaluation joint erosion This strongly proves that USG erosion is a better predictor of joint erosions than the other independent variables(infiammatory markers)
ABSTRACT
Background: Angiotensin receptor blockers are well established drugs for the treatment of hypertension with or without renal disease. Azilsartan is a new angiotensin receptor blocker being used in the treatment of hypertension. Present study is done to evaluate efficacy and safety of azilsartan in patients of hypertension with diabetes mellitus in Gwalior district. Methods: The study was conducted in department of pharmacology, Gajra raja medical college, Gwalior Madhya Pradesh during February 2018 to march 2019. It is a longitudinal, prospective, randomized study and total 90 patients of hypertension with diabetes were enrolled out of which 83 patients completed study with a follow up of 1 year period and were divided equally into two groups. Group I received Azilsartan 40- 80 mg once daily and group II received another drug once daily for 12 weeks. Baseline Systolic blood Pressure and diastolic blood pressure were recorded at the start and then at 4th, 8thand 12th weeks after therapy. Fasting and post prandial blood sugar, HDL, LDL-C , total cholesterol values were recorded at start and after 12 weeks of therapy. All the patients were screened for any adverse drug reactions on each visit. Result: Azilsartan effectively lowered the levels of systolic and diastolic blood pressure from baseline (p=0.00001) confirming the antihypertensive efficacy also there was overall significant improvement in HDL values from baseline (p=0.000) and also significant improvement was shown in LDL Total cholesterol levels from baseline (p =0.005). There was significant improvement in FBS and PPBS from baseline (p value 0.00). Conclusion: Azilsartan effectively lowered the levels of systolic and diastolic blood pressure in patients of hypertension with diabetes and the difference was significant. Azilsartan showed overall improvement in HDL, LDL, TC values with significant difference in hypertensive with diabetes patients.